Inflammation as a Therapeutic Target in Cancer Cachexia
Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5262 |
| _version_ | 1797468873567502336 |
|---|---|
| author | Gerald Clamon Margaret M. Byrne Erin E. Talbert |
| author_facet | Gerald Clamon Margaret M. Byrne Erin E. Talbert |
| author_sort | Gerald Clamon |
| collection | DOAJ |
| description | Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy. |
| first_indexed | 2024-03-09T19:13:32Z |
| format | Article |
| id | doaj.art-ab6bf5b24c684b3aa5861a9b2e2589fc |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:13:32Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ab6bf5b24c684b3aa5861a9b2e2589fc2023-11-24T04:01:37ZengMDPI AGCancers2072-66942022-10-011421526210.3390/cancers14215262Inflammation as a Therapeutic Target in Cancer CachexiaGerald Clamon0Margaret M. Byrne1Erin E. Talbert2Department of Internal Medicine, Division of Hematology/Oncology, Marrow and Stem Cell Transplantation and Cellular Therapy, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USADepartment of Internal Medicine, Division of Hematology/Oncology, Marrow and Stem Cell Transplantation and Cellular Therapy, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USADepartment of Health and Human Physiology, University of Iowa, 285 Newton Road, Iowa City, IA 52242, USACachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy.https://www.mdpi.com/2072-6694/14/21/5262cancer-associated weight losstissue wastingcytokines |
| spellingShingle | Gerald Clamon Margaret M. Byrne Erin E. Talbert Inflammation as a Therapeutic Target in Cancer Cachexia Cancers cancer-associated weight loss tissue wasting cytokines |
| title | Inflammation as a Therapeutic Target in Cancer Cachexia |
| title_full | Inflammation as a Therapeutic Target in Cancer Cachexia |
| title_fullStr | Inflammation as a Therapeutic Target in Cancer Cachexia |
| title_full_unstemmed | Inflammation as a Therapeutic Target in Cancer Cachexia |
| title_short | Inflammation as a Therapeutic Target in Cancer Cachexia |
| title_sort | inflammation as a therapeutic target in cancer cachexia |
| topic | cancer-associated weight loss tissue wasting cytokines |
| url | https://www.mdpi.com/2072-6694/14/21/5262 |
| work_keys_str_mv | AT geraldclamon inflammationasatherapeutictargetincancercachexia AT margaretmbyrne inflammationasatherapeutictargetincancercachexia AT erinetalbert inflammationasatherapeutictargetincancercachexia |